Read by QxMD icon Read

Spasticity AND dysport

Dirk Dressler, Fereshte Adib Saberi
BACKGROUND: AbobotulinumtoxinA (Dysport®) was distributed for many years in vials containing 500MU (D500). Recently a new 300MU vial (D300) was additionally introduced (introduction). We wanted to explore whether more differentiated package sizes allow for more economic use of Dysport® in a large neurological botulinum toxin (BT) outpatient clinic. METHODS: The study followed a retrospective chart review design based on our digital BT therapy data bank. All patients receiving Dysport® exclusively in a constant dose during the observation period (introduction ± 7 months) were included...
2017: Journal of Clinical Movement Disorders
Samira Lahrabli, Herman Azanmasso, Fatima Lmidmani, Abdellatif El Fatimi
OBJECTIVE: Intramuscular injection of botulinum toxin can be painful for some patients. This may be due either to a broken skin, stimulation for locating, or injecting the product. The objective of this study was to see the clinical impact of pain on injection. MATERIAL/PATIENTS AND METHODS: Retrospective study of 15 patients (6 M/9 W), average age was 31 years (11-75 years). The patients had spasticity of MS in 40% and a MI spasticity in 60%. The treatment was basic Dysport...
September 2016: Annals of Physical and Rehabilitation Medicine
Aurélie Rochefolle, Emmanuelle Carré, Aurélie Rochefolle, Marie Callies de Sallies, Florence Durand, Catherine Rioufol, Jacques Luaute, Gilles Rode
OBJECTIVE: Botulinum toxins are often prescribed in aftercare and neurological rehabilitation services. In our hospital, they are exponentially used in the treatment of spasticity. The objective of this study is to make an assessment of their use over the period 2012-2015. MATERIAL/PATIENTS AND METHODS: All the botulinum toxin prescriptions are followed by the chemists. A traceability form allows to collect information about the patient, the prescriber, the medicine and its dose, the cost, and the indication...
September 2016: Annals of Physical and Rehabilitation Medicine
Dennis Matthews, George C Camba, Ignacio Pascual-Pascual, Ann H Tilton, Mark Gormley, Adnan Mahmood, Philippe Picaut, Daniel Snyder, Mauricio R Delgado
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Christina Marciniak, Fatma Gul, Ziyad Ayyoub, David M Simpson, Heather W Walker, Michael Wimmer, Claire Vilain, Jean-Michel Graciès
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Fatma Gul, Michael O'Dell, Robert Jech, Marta Banach, Claire Vilain, Anne-Sophie As Grandoulier, Jean-Michel Germain, Jean-Michel Graciès
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Francesco Scaglione
Botulinum neurotoxin has revolutionized the treatment of spasticity and is now administered worldwide. There are currently three leading botulinum neurotoxin type A products available in the Western Hemisphere: onabotulinum toxin-A (ONA) Botox(®), abobotulinum toxin-A (ABO), Dysport(®), and incobotulinum toxin A (INCO, Xeomin(®)). Although the efficacies are similar, there is an intense debate regarding the comparability of various preparations. Here we will address the clinical issues of potency and conversion ratios, as well as safety issues such as toxin spread and immunogenicity, to provide guidance for BoNT-A use in clinical practice...
March 4, 2016: Toxins
Yu N Ponomarenko, S V Vasenko, A M Nenko
The study analyses results of treatment of 196 patients, with cerebral palsy, which underwent a course of health-resort treatment is performed. Past medical history of patients for the last 10 years was also analysed. It was found that the use of botulin toxin <A> (BT-A) <Dysport®> as a part of complex rehabilitation of the patients significantly improved the effectiveness of the treatment. It was determined that the reasons of the lack of spasticity reduce are caused by degeneration of the muscles...
August 2015: Voenno-medit︠s︡inskiĭ Zhurnal
S E Khat'kova, D R Khasanova, L A Korenko, L N Antipova, L P Shperling, D V Popov, D V Pokhabov, E V Poznyakova
AIM: To assess the efficacy of Botulinum toxin type A (BoNT-A) injections in routine practice. MATERIAL AND METHODS: An international, post-marketing, multi-center, observational, prospective, longitudinal study included patients ≥18 years with poststroke upper-limb spasticity in whom a decision to inject BoNT-A had already been made, and who had no previous treatment with BoNT-A or BoNT-B within the last 12 weeks. The responder rate was assessed by the patient-centered goal attainment scaling (GAS)...
2015: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Z A Zalialova
The most frequent causes of disability of patients with neurological diseases are motor disorders in the upper motor neuron lesion caused by the damage of the brain and/or the spinal cord that resulted in the formation of spastic paresis and paralysis. The correct understanding of the pathophysiological basis of clinical presentations of the upper motor neuron lesion will allow to chose the most adequate and prognostically successful methods of treatment. Currently, treatment with botulotoxin can be considered as such a method...
2014: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Mark de Niet, Susanne T de Bot, Bart P C van de Warrenburg, Vivian Weerdesteyn, Alexander C Geurts
OBJECTIVE: Although calf muscle spasticity is often treated with botulinum toxin type-A, the effects on balance and gait are ambiguous. Hereditary spastic paraplegia is characterized by progressive spasticity and relatively mild muscle weakness of the lower limbs. It is therefore a good model to evaluate the functional effects of botulinum toxin type-A. DESIGN: Explorative pre-post intervention study. SUBJECTS: Fifteen subjects with pure hereditary spastic paraplegia...
February 2015: Journal of Rehabilitation Medicine
F de Andrés-Nogales, A Morell, J Aracil, C Torres, I Oyagüez, M A Casado
OBJECTIVE: To estimate treatment costs of blepharospasm, cervical dystonia(CD), upper limb spasticity (ULS) and spasticity in children with cerebral palsy (SCCP) with botulinum neurotoxin type A (BoNT-A) in Spain. METHOD: Annual BoNT-A treatment costs were calculated (2013 ex-factory price () applying RDL 8/2010 and RDL 9/2011 deductions), based on initial dose (id), average dose (ad) and maximum dose (md) according to Summary of Product Characteristics of Botox® (100U/50U), Dysport®(500U) and Xeomin® (100U) and considering the use of complete vials...
May 2014: Farmacia Hospitalaria
Mohsen Bahmani Kashkouli, Afsaneh Amani, Mansooreh Jamshidian-Tehrani, Sahar Yousefi, Anis Alsadat Jazayeri
PURPOSE: To report the method and results of 18-point Abobotulinum toxin A (ABO-BTA, Dysport) upper face rejuvenation on 845 subjects. METHODS: In a retrospective chart review, all subjects (the first cycle of injection) with ABO-BTA upper face rejuvenation from 2003 to 2009 were included. Excluded were subjects with facial spastic disorders, injection after upper face lifting, and aberrant regeneration of facial nerves. Upper face rejuvenation included 18 points of injection at forehead creases (4), frown lines (5), bunny line (1), crow's feet (4 on both sides), and lower eyelid crease (4 on both sides)...
May 2014: Ophthalmic Plastic and Reconstructive Surgery
Wolfgang H Jost, Harald Hefter, Andrea Reissig, Katja Kollewe, Joerg Wissel
The current practice in Germany and Austria, and the safety and efficacy of botulinum toxin type A (BoNT-A; Dysport) in the treatment of patients with post-stroke arm spasticity (with no fixed upper-limb contractures), were assessed in this observational prospective non-interventional study. One treatment cycle was documented with assessments at baseline, approximately week 4 (optional), and approximately week 12. Pattern of spasticity, treatment goal, safety and efficacy were recorded. Overall response and goal achievement was rated on a 4-point scale ('no goal achievement', 'goal achievement', 'good goal achievement', 'best goal achievement')...
February 15, 2014: Journal of the Neurological Sciences
Mohammad Yazdchi, Zahra Ghasemi, Hanieh Moshayedi, Reza Rikhtegar, Somayeh Mostafayi, Hale Mikailee, Safa Najmi
BACKGROUND: This study evaluated the efficacy of focal intramuscular injection of botulinum (BoNT) toxin type A in comparison with oral tizanidine (TZD) in treatment of post-stroke upper limb spasticity. METHODS: This was a double-blinded randomized clinical trial that recruited 68 patients with post-stroke upper limb spasticity. Thirty-four patients received BoNT (Dysport(®)) injections in affected muscles of upper limb at the baseline and week 12. Thirty-four patients were treated with tizanidine (Sirdalude) by gradual increase in dosage of 2mg/week to reach maximum 24mg at week 12...
2013: Iranian Journal of Neurology
Jean Hubble, Joseph Schwab, Catherine Hubert, Chandra Coleman Abbott
BACKGROUND: Botulinum neurotoxin type A is a well-established treatment for a number of conditions involving muscle hyperactivity. Dysport (Ipsen Ltd, Wrexham, United Kingdom) is a botulinum neurotoxin type A preparation that has been available for a number of therapeutic uses for over 20 years in the European Union (EU). This survey was part of the EU botulinum toxin risk management plan to identify potential educational needs of injectors by collecting data on their routine practice administration of Dysport and their awareness of potential adverse events (AEs) that are included in the current product labeling...
July 2013: Clinical Neuropharmacology
Roberta Ravenni, Domenico De Grandis, Alberto Mazza
The optimal conversion ratio between Dysport and Botox--the two botulinum neurotoxin type A products (BoNT-As) supported by the larger bulk of evidence-has been extensively debated, because of its broad medical and economic implications. The article discusses the available evidence on the conversion ratio between Dysport and Botox in adults affected by spasticity, cervical dystonia, blepharospasm and hemifacial spasm, with a focus on clinical trials that specifically addressed this issue. In addition, some suggestions on the conversion ratio between Dysport and Xeomin can be extrapolated, since Xeomin has the same efficacy and safety profile as Botox and is exchangeable with Botox with a 1:1 conversion ratio...
July 2013: Neurological Sciences
Stéphane Roze, Hannah Kurth, Barnaby Hunt, William Valentine, Rémi Marty
BACKGROUND: Botulinum toxin A injections are indicated for the management of movement disorders, including upper limb spasticity. The aim of this study was to compare the cost per patient per injection for two botulinum toxin A preparations in 19 countries. METHODS: Doses of botulinum toxin A are expressed in noninterchangeable units (U), ie, Botox(®) in 100 Allergan units (100 U) and Dysport(®) in 500 Speywood units (500 U). Recommended dosages were derived from country-specific summaries of product characteristics or prescribing information...
2012: Medical Devices: Evidence and Research
David Charles, Chandler E Gill
The therapeutic use of botulinum neurotoxin has exploded since the first US Food and Drug Administration indication was obtained in 1989, and today it represents the first-line therapy for several hyperkinetic movement disorders. Of the seven serotypes (A to G), types A and B have been approved for use in the United States. Two type A toxins, onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport), are available, and one type B toxin, rimabotulinumtoxinB (Myobloc) is available. The commercially available toxins differ by protein target, duration of action, and adverse event profile; no formula exists for interconversion...
February 2010: Continuum: Lifelong Learning in Neurology
Raymond L Rosales, Keng He Kong, Khean Jin Goh, Witsanu Kumthornthip, Vincent Chung Tong Mok, Mary Mildred Delgado-De Los Santos, Karen Sui Geok Chua, Saini Jeffery Bin Freddy Abdullah, Benjamin Zakine, Pascal Maisonobe, Axel Magis, K S Lawrence Wong
BACKGROUND: Botulinum neurotoxin type A (BoNT-A) reduces upper-extremity poststroke spasticity when given 6 or more months after stroke. Effects on functional use of the arm and hand are less apparent. OBJECTIVE: To determine the effect and safety of very early use of BoNT-A for patients with upper-limb spasticity. METHODS: The Asia Botulinum Toxin-A Clinical Trial DESIGN: ed for Early Post-stroke Spasticity (ABCDE-S; NCT00234546) was a multicenter, randomized, placebo-controlled trial conducted in patients recruited within 2 -12 weeks of first-ever stroke...
September 2012: Neurorehabilitation and Neural Repair
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"